The Foundry, Inc.

Terumo Kabushiki Kaisha

Medtronic Ardian Luxembourg S.a.r.l.

Ethicon Endo-surgery, Inc.

Evalve, Inc.

Xtent, Inc.

Twelve, Inc.

Ulthera, Inc.

Transcend Medical, Inc.

Pulmonx Corporation

J.w. Medical Systems Ltd.

Medtronic Ireland Manufacturing Unlimited Company

Other

Alcon, Inc.

Novartis Ag

Mark E Deem

Hanson S Gifford, Iii

Hanson Gifford

Bernard H Andreas

Douglas S Sutton

Ronald G French

William W Malecki

Kenneth N Horne

Douglas Sutton

Jose D Alejandro

Steven W Kim

Jessi E Johnson

Mark Gelfand

Howard R Levin

Denise Marie Zarins

Erik Thai

Martin S Dieck

Stephen A Boyd

Ted Y Su

Allan R Will

Eric A Goldfarb

Martin L Mayse

Kent D Dell

Ferolyn T Powell

John H Morriss

Eugene De Juan, Jr

Brian Benjamin Martin

Steven Charles Dimmer

Adnan I Merchant

Michael Luna

Craig R Gerbi

Erik T Engelson

Jean-Pierre Dueri

Darin Charles Gittings

David W Snow

Gary B Weller

Antony Jonathan Fields

James R Gannoe

Alan R Rapacki

Ronald Ray Hundertmark

Ivan Sepetka

Michael J Hendricksen

Peter M Wilson

James E Chomas

Mark Y Hirotsuka

Dan Francis

Alexey Salamini

Ron French

Daniel Elliott Francis

Sunmi Chew

Frederick G St Goar

Peter Smith

James I-Lin Fann

Jeffry J Grainger

Sylvia Wen-Chin Fan

Daniel K Hallock

Dan Rosenman

James I Fann

Yoav Ben-Haim

Doug Sutton

Shailendhar Saraf

Vijaykumar Rajasekhar

Uday N Kumar

Miriam H Taimisto

Dominique Filloux

Dan Hallock

Michael Barrett

Robert George

Eugene De Juan

Stephen Kao

Brain B Martin

Venkata Vegesna

Jeffrey J Dolin

Alan Will

Jose Alegandro

James L Fann

Darrin Gittings

Sylvia Wenchin Fan

Alexey Salaminí

Kenneth Home

Jessi Ernest Johnson

Hanson S Gifford Iii

Hanson S Iii Gifford

Stephen Boyd

Hanson Iii Gifford

Jeffrey J Grainger

Daniel Hallock

Hansen S Iii Gifford

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

Systems and methods for delivery of a therapeutic agent

A heart valve repair device may include a support configured to extend through a native annulus of a native heart valve, wherein the support comprises an upstream portion and a downstream portion; an annular expandable retainer extending from the upstream portion of the support, and an arm extending from the downstream portion of the support. The annular expandable retainer may include a C-shaped cross-section that is open inwardly. The arm may be configured to reach behind a leaflet of the native heart valve and sandwich the leaflet between the arm and the support.

Devices, systems and methods for heart valve replacement

Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.

Glaucoma treatment device

Systems, delivery devices, and methods to treat to ablate, damage, or otherwise affect tissue. The treatment systems are capable of delivering a coolable ablation assembly that ablates targeted tissue without damaging non-targeted tissue. The coolable ablation assembly damages nerve tissue to temporarily or permanently decrease nervous system input. The system, delivery devices, and methods can damage tissue and manage scarring and stenosis.

Systems, apparatuses, and methods for treating tissue and controlling stenosis

Methods, apparatuses and systems are provided for non-invasive delivery of microwave therapy. Microwave energy may be applied to epidermal, dermal and subdermal tissue of a patient to achieve various therapeutic and/or aesthetic results. In one embodiment, the microwave energy is applied to a target tissue via an energy delivery applicator connected to an energy generator. The energy delivery applicator may comprise one or more antennas, including monopole, dipole, slot and/or waveguide antennas (among others) that are used to direct the microwave energy to the target tissue. The energy delivery applicator may also comprise a cooling element for avoiding thermal destruction to non-target tissue and/or a suction device to localize thermal treatment at specific portions of a skin fold.

Methods, devices, and systems for non-invasive delivery of microwave therapy

Systems for mitral valve repair are disclosed where one or more mitral valve interventional devices may be advanced intravascularly into the heart of a patient and deployed upon or along the mitral valve to stabilize the valve leaflets. The interventional device may also facilitate the placement or anchoring of a prosthetic mitral valve implant. The interventional device may generally comprise a distal set of arms pivotably and/or rotating coupled to a proximal set of arms which are also pivotably and/or rotating coupled. The distal set of arms may be advanced past the catheter opening to a subannular position (e.g., below the mitral valve) and reconfigured from a low-profile delivery configuration to a deployed securement configuration. The proximal arm members may then be deployed such that the distal and proximal arm members may grip the leaflets between the two sets of arms to stabilize the leaflets.

System for mitral valve repair and replacement

Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.

Bilateral renal neuromodulation

Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.

Methods and apparatus for renal neuromodulation

Systems, delivery devices, and methods to treat to ablate, damage, or otherwise affect tissue. The treatment systems are capable of delivering energy to nerve tissue in a target region such that at least a portion of the nerve tissue is replaced by scar tissue or otherwise altered to inhibit reinnervation in the target region.

Apparatuses and methods for injuring nerve tissue

Growing community of inventors

Mountain View, CA, United States of America

Mark E Deem